VIR
Vir Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.39
−0.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 303.2M | 68.6M | 74.2M | 86.2M | 1.6B |
| Cost of Revenue | (212.3M) | 11.7M | 478.6M | 572.8M | 621.0M |
| Gross Profit | 515.5M | 56.9M | (404.4M) | (486.6M) | 994.8M |
| Operating Expenses | |||||
| R&D Expense | 484.0M | 432.8M | 506.5M | 579.7M | 474.6M |
| SG&A Expense | 99.4M | 92.1M | — | — | — |
| General & Admin Expense | 30.2M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 201.9M | — | (323.8M) | (382.1M) | (312.9M) |
| Total Operating Expenses | 785.3M | 524.9M | 182.7M | 197.7M | 161.8M |
| Cost and Expenses | 573.0M | 536.6M | 661.4M | 770.5M | 782.7M |
| Operating Income (EBIT) | (269.8M) | (468.0M) | (587.2M) | (684.3M) | 833.1M |
| Non-Operating | |||||
| Interest Income | 33.3M | 40.2M | 71.8M | 87.0M | 28.1M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 33.3M | 40.2M | 71.8M | 87.0M | 28.1M |
| Other Non-Op Income/Expense | 18.5M | 30.3M | 64.1M | 56.1M | (78.8M) |
| Non-Operating Income (excl Interest) | (13.9M) | (30.3M) | (63.7M) | (23.2M) | 78.8M |
| EBT (Pre-Tax Income) | (251.3M) | (437.8M) | (523.1M) | (628.2M) | 754.3M |
| Income Tax Expense | 380.0K | 217.0K | (1.1M) | (13.1M) | 238.4M |
| Bottom Line | |||||
| Net Income | (251.7M) | (438.0M) | (522.0M) | (615.1M) | 515.8M |
| Earnings from Cont. Ops | (251.7M) | (438.0M) | (522.0M) | (615.1M) | 515.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (251.7M) | (438.0M) | (522.0M) | (615.1M) | 515.8M |
| Per Share | |||||
| Basic EPS | ($1.85) | ($3.16) | ($3.83) | ($4.59) | $3.89 |
| Diluted EPS | ($1.86) | ($3.16) | ($3.83) | ($4.59) | $3.83 |
| Revenue Per Share | $1.81 | $0.49 | $0.54 | $0.64 | $12.18 |
| Shares | |||||
| Basic Shares Outstanding | 167.7M | 138.5M | 136.2M | 134.1M | 132.6M |
| Diluted Shares Outstanding | 168.9M | 138.5M | 136.2M | 134.1M | 134.8M |
| Profitability Metrics | |||||
| EBITDA | (244.4M) | (426.1M) | (508.9M) | (641.6M) | 761.1M |
| D&A | 11.5M | 11.7M | 14.6M | 19.5M | 6.8M |
| EBIT | (255.9M) | (437.8M) | (523.5M) | (661.1M) | 754.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026